Breaking News, Collaborations & Alliances

Transition, Lilly in Osteoarthritis Alliance

Transition acquires rights to TT-601

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Transition Therapeutics has entered an exclusive licensing agreement for worldwide rights to a small molecule transcriptional regulator (TT-601) from Eli Lilly and Co. for the treatment of osteoarthritis (OA) pain. TT-601 has completed preclinical development and Transition plans to initiate clinical trials in 1H14.   Transition has acquired the rights to develop and commercialize TT-601 and Lilly retains an option to reacquire all rights following clinical proof-of-concept study results. If Lil...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters